35.3 Celiac Disease & Malabsorption Syndromes

Pathophysiology & Genetic Architecture of Celiac Disease

Celiac disease (gluten-sensitive enteropathy) is an immune-mediated systemic inflammatory disorder triggered by the dietary ingestion of gluten proteins in genetically susceptible individuals. It affects approximately 1% of the global population, with an estimated 60% to 70% of affected individuals in the United States remaining undiagnosed due to atypical, non-classical, or subclinical presentations.

Molecular Immunopathogenesis

1. The Antigenic Culprit (Gluten):
   • Gluten is the major storage protein found in wheat (gliadins and glutenins), barley (hordeins), and rye (secalins). (Oats contain avenins, which are non-toxic in >95% of patients unless contaminated during agricultural milling).
   • The gliadin fraction is exceptionally rich in proline and glutamine residues. Because human gastric pepsins, pancreatic endopeptidases, and brush-border carboxypeptidases lack the enzymatic capacity to cleave post-proline peptide bonds, an intact 33-mer gliadin peptide survives luminal enzymatic digestion.
2. Deamidation by Tissue Transglutaminase-2 (tTG-2):
   • Surviving gliadin fragments breach the intestinal epithelial barrier via paracellular transudation or transcellular endocytosis into the lamina propria.
   • In the lamina propria, the endogenous calcium-dependent enzyme tissue Transglutaminase-2 (tTG-2) post-translationally deamidates neutral glutamine residues into negatively charged glutamic acid.
3. MHC Class II Recognition & T-Cell Activation:
   • Negatively charged deamidated gliadin peptides fit with high stereochemical affinity into the positively charged peptide-binding grooves of Human Leukocyte Antigen (HLA) class II heterodimers: HLA-DQ2 (encoded by DQA1*05:01 and DQB1*02:01, present in 90-95% of celiac patients) or HLA-DQ8 (encoded by DQA1*03:01 and DQB1*02:02, present in 5-10%).
   • Antigen-presenting cells (dendritic cells and macrophages) present these peptides to CD4+ T-helper cells, which trigger a vigorous Th1/Th17 immune response characterized by the secretion of interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-21.
4. Enterocyte Destruction & Humoral Response:
   • Concurrently, enterocytes stressed by gliadin upregulate Interleukin-15 (IL-15) and surface non-classical MHC molecules (MICA/MICB). IL-15 reprograms CD8+ cytotoxic intraepithelial lymphocytes (IELs) into natural killer-like killer cells expressing NKG2D receptors, which directly lyse enterocytes, leading to progressive mucosal architectural destruction.
   • Activated B cells differentiate into plasma cells that synthesize antibodies directed against deamidated gliadin peptides (DGP) and the autoantigen tissue transglutaminase (anti-tTG), as well as anti-endomysial antibodies (EMA).

Histopathologic Marsh Staging

Confirmatory duodenal histology is staged using the validated Marsh-Oberhuber criteria:

• Marsh 0 (Pre-infiltrative): Normal mucosal architecture.
• Marsh 1 (Infiltrative): Normal villous architecture, but intraepithelial lymphocytosis (>25 IELs per 100 enterocytes).
• Marsh 2 (Hyperplastic): Intraepithelial lymphocytosis accompanied by crypt hyperplasia (elongated crypts with increased mitotic figures).
• Marsh 3 (Destructive - Diagnostic Hallmark): Intraepithelial lymphocytosis, crypt hyperplasia, and progressive villous atrophy:
  • Marsh 3a: Partial villous blunting;
  • Marsh 3b: Subtotal villous atrophy (stunted, thin villi);
  • Marsh 3c: Total villous atrophy (completely flat mucosa with total loss of villous projections, resembling colonic architecture).

---

Clinical Spectrum: Classic, Non-Classic & Dermatitis Herpetiformis

The clinical presentation of celiac disease has shifted dramatically over recent decades. The historic paradigm of a severely wasted infant with protuberant abdomen and foul steatorrhea now represents the minority of adult cases.

1. Classic (Malabsorptive) Celiac Disease

• Presents with overt symptoms of intestinal malabsorption: chronic watery or greasy diarrhea, steatorrhea (pale, voluminous, malodorous floating stools), significant unintentional weight loss, abdominal distension, muscle wasting, and severe nutritional deficiencies.
• Fat-soluble vitamin malabsorption:
  • Vitamin A deficiency: Night blindness (nyctalopia), xerophthalmia, follicular hyperkeratosis;
  • Vitamin D & Calcium deficiency: Hypocalcemia, secondary hyperparathyroidism, osteomalacia, tetany;
  • Vitamin E deficiency: Peripheral neuropathy, spinocerebellar ataxia, hemolytic anemia;
  • Vitamin K deficiency: Hypoprothrombinemia, elevated INR, easy bruising, ecchymoses, hematuria.

2. Non-Classic (Extraintestinal) Celiac Disease

Now accounting for >60% of newly diagnosed adult cases in primary care. Patients have minimal or no overt gastrointestinal symptoms, presenting instead with subtle extraintestinal signs:

• Refractory Iron Deficiency Anemia: The most common extraintestinal manifestation. Because dietary iron is absorbed almost exclusively in the duodenum and proximal jejunum (the anatomical epicenter of celiac villous destruction), impaired enterocyte iron transport leads to microcytic anemia that fails to respond to oral iron supplementation.
• Metabolic Bone Disease: Early-onset osteopenia, osteoporosis, or low-trauma fragility fractures in young adults or premenopausal women, driven by chronic calcium malabsorption and vitamin D deficiency.
• Unexplained Transaminitis ("Celiac Hepatitis"): Asymptomatic, mild-to-moderate elevations in serum AST and ALT (typically 1.5 to 3 times upper limit of normal) found in up to 10% to 15% of patients. In >80% of cases, liver enzymes normalize completely within 6 to 12 months on a strict gluten-free diet.
• Neurologic & Psychiatric Manifestations: Symmetric distal sensory peripheral neuropathy, gluten ataxia (cerebellar ataxia with Purkinje cell loss and anti-gliadin antibodies), intractable migraine headaches, anxiety, and depression.
• Oral & Cutaneous Signs: Recurrent, painful aphthous stomatitis (oral ulcers) and permanent dental enamel hypoplasia (pitting or yellow/brown horizontal grooves affecting secondary teeth).
• Reproductive Dysfunction: Unexplained primary or secondary infertility, recurrent spontaneous miscarriages, intrauterine growth restriction (IUGR), and delayed menarche.

3. Dermatitis Herpetiformis: The Pathognomonic Cutaneous Manifestation

• Clinical Presentation: Intensely pruritic, burning, stinging erythematous macules, urticarial papules, and grouped vesicles ("herpetiform" clusters) distributed symmetrically over the extensor surfaces:
  • Elbows and forearms (90%)
  • Knees and shins (30%)
  • Buttocks and natal cleft (80%)
  • Posterior scalp and upper back.
• Pathognomonic Diagnostic Test: Direct Immunofluorescence (DIF) performed on a punch biopsy of perilesional (normal-appearing) skin adjacent to an active lesion.
  • Microscopic Finding: Sinuous, granular IgA deposits localized to the dermal papillae along the dermal-epidermal junction.
• Gastrointestinal Correlation: Over 90% of patients with dermatitis herpetiformis have biopsy-confirmed intestinal enteropathy (villous atrophy), although gastrointestinal symptoms are frequently subclinical or mild.
• Clinical Mandate: A definitive diagnosis of dermatitis herpetiformis via skin biopsy is diagnostic of celiac disease; confirmatory duodenal biopsy is not strictly required.
• Therapeutic Strategy:
  • Oral Dapsone (50 to 100 mg daily): Provides dramatic symptomatic relief, arresting pruritus and resolving skin lesions within 24 to 72 hours by inhibiting neutrophil chemotaxis and myeloperoxidase release. Check G6PD enzyme level prior to initiation to prevent severe drug-induced hemolytic anemia.
  • Strict Lifelong Gluten-Free Diet: Dapsone treats only the cutaneous symptoms and has zero effect on intestinal mucosal damage or lymphoma risk. A strict gluten-free diet heals the intestinal mucosa and, over 6 to 24 months, eliminates cutaneous IgA clearance, allowing dapsone to be successfully tapered and discontinued.

---

Diagnostic Testing Protocol & The Selective IgA Deficiency Pitfall

Establishing an accurate diagnosis requires a structured serologic and endoscopic algorithm while adhering to critical pre-test dietary rules:

                      CELIAC DISEASE DIAGNOSTIC PROTOCOL

          Patient Suspected of Celiac Disease (Must be ON Gluten Diet!)
                                      │
                                      ▼
                  Order FIRST-LINE Serologic Screening:
                  • Serum Tissue Transglutaminase IgA (anti-tTG IgA)
                  • PLUS Total Serum IgA Level
                                      │
               ┌──────────────────────┴──────────────────────┐
               ▼                                             ▼
      Total Serum IgA NORMAL                     Total Serum IgA DEFICIENT
        (IgA Sufficient)                              (IgA <20 mg/dL)
               │                                             │
        ┌──────┴──────┐                               ┌──────┴──────┐
        ▼             ▼                               ▼             ▼
    anti-tTG IgA   anti-tTG IgA                   DGP IgG or     DGP IgG or
      POSITIVE       NEGATIVE                    anti-tTG IgG   anti-tTG IgG
        │             │                            POSITIVE       NEGATIVE
        │        Celiac Unlikely                      │             │
        │        (Look for SIBO/EPI)                  │        Celiac Unlikely
        │                                             │
        └──────────────────────┬──────────────────────┘
                               │
                               ▼
               Confirmatory Upper Endoscopy (EGD)
               • Multiple Duodenal Biopsies:
                 - 1 to 2 biopsies from Duodenal Bulb
                 - At least 4 biopsies from Distal Duodenum (D2/D3)
               • Histology: Marsh 1-3 (Villous atrophy, crypt hyperplasia)
                               │
                               ▼
                  Initiate Lifelong Strict GFD

1. First-Line Serology & Total IgA Requirement

• Tissue Transglutaminase IgA (anti-tTG IgA):
  • Sensitivity: 95% to 98%; Specificity: 95% to 98%.
  • The single preferred first-line serologic test for patients aged >2 years.
• Total Serum IgA Measurement:

  • [!IMPORTANT]

  • THE SELECTIVE IgA DEFICIENCY PITFALL: Selective IgA deficiency occurs in 2% to 3% of patients with celiac disease, representing a 10- to 15-fold higher prevalence than in the general population (where it occurs in ~1:600).
  • In an IgA-deficient patient, the immune system cannot produce IgA antibodies; consequently, anti-tTG IgA and anti-endomysial IgA will be FALSELY NEGATIVE, leading to missed diagnoses and progressive untreated disease.
  • Mandatory Clinical Protocol: Every celiac serologic screening panel must include Total Serum IgA.
  • If Total Serum IgA is below the lower limit of normal (<20 mg/dL), reflex testing must immediately evaluate IgG-based serology: Deamidated Gliadin Peptide IgG (DGP IgG) OR anti-tTG IgG.
• Anti-Endomysial IgA Antibodies (EMA-IgA):
  • Binds to tTG in the perimysium of smooth muscle. Highest specificity (near 100%), but lower sensitivity in early disease and requires indirect immunofluorescence (operator-dependent). Used primarily as a confirmatory secondary test.

2. THE CRITICAL GLUTEN CHALLENGE RULE

[!CAUTION] NEVER INITIATE A GLUTEN-FREE DIET PRIOR TO DIAGNOSTIC TESTING! All serologic antibody titers (anti-tTG, anti-DGP) and endoscopic intestinal mucosal lesions depend strictly on ongoing dietary gluten exposure. When gluten is eliminated, antibody titers decline exponentially (half-life of anti-tTG is ~30 to 60 days) and duodenal villous architecture completely normalizes, producing falsely negative serology and histologically normal biopsies.

The Standard Gluten Challenge Protocol: If a symptomatic patient has already placed themselves on a gluten-free diet before testing, they must undergo a formal gluten challenge:

• Consume at least 3 to 10 grams of dietary gluten daily (equivalent to 1 to 2 slices of standard wheat bread or one bowl of wheat pasta daily);
• Continue this active consumption for a minimum of 6 to 12 weeks;
• Serologic testing and duodenal biopsies are then performed while actively on this diet.

3. Confirmatory Esophagogastroduodenoscopy (EGD) & Duodenal Biopsy Protocol

In adult clinical practice, definitive confirmation of celiac disease requires an upper endoscopy with mucosal biopsy:

• Biopsy Sampling Requirements:
  • Because celiac villous atrophy can be focal or patchy, inadequate sampling leads to false-negative pathology.
  • At least 1 to 2 biopsies must be taken from the duodenal bulb (often the only site of involvement, classically at the 9- or 12-o'clock position);
  • PLUS at least 4 biopsies from the second and third portions of the distal duodenum (D2/D3).
  • A minimum total of 5 to 6 biopsies is required.
• Endoscopic Visual Clues:
  • Scalloping of duodenal mucosal folds;
  • Mosaic or cracked-clay mucosal pattern;
  • Flattened, reduced, or absent duodenal circular folds (valvulae conniventes);
  • Mucosal nodularity.

4. Utility & Interpretation of HLA-DQ2 / HLA-DQ8 Genetic Testing

• Human leukocyte antigen (HLA) genotyping detects the alleles encoding HLA-DQ2 (DQA1*05:01, DQB1*02:01) and HLA-DQ8 (DQA1*03:01, DQB1*03:02).
• High Sensitivity & Negative Predictive Value (>99%):
  • Over 99% of celiac patients carry HLA-DQ2 or HLA-DQ8. If a patient tests negative for both HLA-DQ2 and HLA-DQ8, celiac disease is virtually 100% ruled out.
• Low Specificity & Positive Predictive Value (~12-15%):
  • Approximately 30% to 40% of the healthy, asymptomatic general population carries HLA-DQ2 or DQ8 without ever developing celiac disease. Therefore, a positive HLA test is NOT diagnostic and only indicates genetic susceptibility.
• Appropriate Clinical Indications for HLA Testing:
  1. Resolving diagnostic ambiguity when serology and duodenal histology are discordant (e.g., positive serology with Marsh 0-1 histology);
  2. Evaluating a patient already established on a strict gluten-free diet who is unwilling or unable to undergo a formal 6-to-12-week gluten challenge (a negative result conclusively rules out celiac disease, avoiding the need for a challenge);
  3. Screening asymptomatic individuals in high-risk populations (first-degree relatives of celiac patients, Type 1 diabetics, Down syndrome, Turner syndrome, autoimmune thyroiditis) to rule out future susceptibility.

---

Long-Term Management, Surveillance & Health Maintenance

Celiac disease is a chronic systemic condition requiring lifelong vigilance to prevent malignant transformation (enteropathy-associated T-cell lymphoma [EATL] and small bowel adenocarcinoma) and nutritional failure.

1. The Lifelong Strict Gluten-Free Diet (GFD)

• Complete, permanent avoidance of all dietary products containing wheat, rye, and barley (including hidden additives: malt, malt extract, hydrolyzed wheat protein, soy sauces brewed with wheat, beer, ale, and food thickeners).
• Pure, uncontaminated oats (certified gluten-free) are safe and well-tolerated by >95% of patients and improve diet quality and dietary fiber intake.
• Consultation with a specialized gastrointestinal registered dietitian experienced in celiac disease is mandatory upon diagnosis.

2. Baseline Nutritional Screening & Bone Mineral Density Evaluation

At the time of diagnosis, all adult patients must undergo baseline screening for malabsorptive micronutrient deficiencies:

• Complete blood count, serum ferritin, total iron-binding capacity (TIBC);
• Serum folate and Vitamin B12;
• 25-hydroxyvitamin D, serum calcium, phosphorus, alkaline phosphatase;
• Serum zinc and copper levels;
• Hepatic panel (AST, ALT) and TSH;
• Dual-Energy X-ray Absorptiometry (DEXA) Scan: Recommended at baseline in all adult celiac patients to screen for osteopenia and osteoporosis; repeat at 2 to 3 years if initial scan is abnormal.

3. Serologic Surveillance & Monitoring Healing

• Measure serum anti-tTG IgA titers at 6 months and 12 months following GFD initiation, and annually thereafter once normalized.
• Antibody titers decline gradually as dietary antigen is eliminated; failure of titers to drop significantly by 6 to 12 months strongly indicates inadvertent or occult gluten exposure (which accounts for >90% of non-responsive celiac disease).
• Repeat upper endoscopy with biopsy is recommended at 2 years for patients with severe initial presentation, persistent symptoms, or persistent seropositivity to document mucosal healing.

4. Pneumococcal Immunization & Functional Hyposplenism

• Functional Hyposplenism: Occurs in up to one-third of adult celiac patients due to splenic reticuloendothelial atrophy, predisposing to catastrophic bacteremia caused by encapsulated organisms, predominantly Streptococcus pneumoniae.
• Immunization Guideline: All adults with celiac disease should receive pneumococcal vaccination (a single dose of PCV20, or PCV15 followed by PPSV23 ≥1 year later).

---

Malabsorption Differential Diagnosis: EPI, SIBO & Lactase Deficiency

When a patient presents with chronic diarrhea, weight loss, bloating, and nutritional failure, celiac disease must be systematically differentiated from other classic malabsorptive entities:

Differential Diagnostic Comparison Table

Clinical Details on Non-Celiac Malabsorption Syndromes

1. Exocrine Pancreatic Insufficiency (EPI):

   • Lipase output must decline by >90% before overt fat malabsorption and steatorrhea occur, because the pancreas has enormous functional reserve.
   • Fecal Elastase-1 (FE-1) is the diagnostic test of choice. Human pancreatic elastase-1 is entirely resistant to degradation during intestinal transit. Unlike 72-hour fecal fat quantification, the FE-1 test requires only a single solid or semi-formed stool sample. Crucially, exogenous pancreatic enzyme replacement therapy does NOT cross-react with the human elastase-1 ELISA assay, meaning the test remains completely accurate even if the patient is already taking PERT.
   • Management: Enteric-coated capsules containing lipase, amylase, and protease (e.g., Creon, Zenpep). Dosing begins at 40,000 to 50,000 USP units of lipase per major meal (and half dose with snacks), taken with the first bites of food. Concurrent proton pump inhibitor (PPI) therapy is often added to suppress gastric acid and prevent premature destruction of enzyme coatings in the duodenum.

2. Small Intestinal Bacterial Overgrowth (SIBO):

   • Bacteria resident in the small bowel deconjugate bile salts, rendering them insoluble and preventing mixed micelle formation, resulting in fat malabsorption. Furthermore, bacteria avidly consume intraluminal Vitamin B12, causing macrocytic megaloblastic anemia. Paradoxically, bacteria synthesize folate and vitamin K, resulting in elevated serum folate levels in the setting of low Vitamin B12 (a classic board exam diagnostic clue!).
   • Diagnosis: Non-invasive carbohydrate breath testing. Ingestion of glucose or lactulose followed by serial end-expiratory breath measurements every 15 minutes for 2 hours. A rise in breath hydrogen of ≥20 parts per million (ppm) or breath methane ≥10 ppm within 90 minutes confirms the diagnosis.
   • Treatment: Oral Rifaximin 550 mg three times daily for 14 days. For methane-positive SIBO (associated with constipation and intestinal methanogen overgrowth [IMO] by Methanobrevibacter smithii), combine rifaximin with oral neomycin (500 mg BID) or oral metronidazole (250 mg TID) for 14 days.

3. Primary Lactose Intolerance (Adult-Type Hypolactasia):

   • Driven by genetically regulated downregulation of lactase gene (LCT) expression occurring after weaning in >70% of the world's population.
   • Undigested lactose disaccharides cannot be absorbed intact across enterocytes. In the small bowel lumen, lactose exerts an osmotic force, drawing fluid into the intestine. In the colon, bacterial fermentation converts lactose into short-chain fatty acids (SCFAs), carbon dioxide, and hydrogen gas.
   • Clinical Clue: Onset of loud borborygmi, crampy abdominal pain, flatulence, and explosive watery diarrhea within 30 minutes to 2 hours following dairy ingestion. Systemic nutrition, fat absorption, and serum laboratory studies are completely normal.